History of the Department of Cardiovascular Medicine
Beaumont Hospital in Royal Oak, Michigan will always be known for being the earliest proponents of catheter-based treatment for acute myocardial infarction. In the 1970s, Dr. Seymour Gordon and Dr. Gerald Timmis were the first to administer intracoronary streptokinase for acute MI. In the late 1980s and early 1990s, Beaumont recruited a team of academic cardiologists including Dr. William O’Neill, Dr. Robert Safian, Dr. Cindy Grines and Dr. James Goldstein, who embarked on a 20-year era of high volume clinical research and numerous landmark publications beginning with the PAMI study, the first major trial of angioplasty compared with thrombolytic therapy for acute MI. Dr. Safian led a variety of clinical studies on percutaneous coronary interventional techniques, including atherectomy, lasers, and stents, and later numerous studies of renal and carotid intervention. Dr. Goldstein studied RV infarction and the effects of reperfusion on the ischemic RV. In 2005, Beaumont was notably the first hospital in North America to perform TAVR.
Joined later by Dr. Simon Dixon, Dr. David Haines, and Dr. Ivan Hanson, the department matured into a powerhouse for novel interventions in several areas:
- Ischemic heart disease: stable and acute ischemic heart diseases, cardiogenic shock, therapeutic temperature management and coronary brachytherapy
- Peripheral arterial disease: acute and chronic limb ischemia, visceral [renal, mesenteric] ischemia, brachiocephalic and carotid disease, and renovascular hypertension
- Structural heart diseases: TAVR, Valve-in-Valve, MitraClip, paravalvular regurgitation, PFO and ASD repair
- Electrophysiology: high volume device implantation, AF and VT ablation, and left atrial appendage occlusion